Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognosticationDavid Miles, Hamdy Abdel Azeem, Eva Ciruelos et al.|Annals of Oncology|2021Cited by 92
A phase III trial of taxotere and doxorubicin (AT) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in patients with unresectable locally advanced breast cancer: an interim analysisK. Bouzid, Nabeel Badri, S. Valdivia et al.|European Journal of Cancer|2001Cited by 10